<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Mtb</italic> represents a particularly difficult challenge for vaccine developers as it appears to both evade host immunity and modulate it in its favor. Accordingly, a successful TB vaccine likely will have to hit 
 <italic>Mtb</italic> infection hard and early, in a manner that prevents 
 <italic>Mtb</italic> from taking control of the host immune response directed against it. A CMV-vectored vaccine strategy offers the potential for accomplishing this by generating “effector-memory” T-cells prepositioned in the lungs, at sites of early pathogen colonization 
 <sup>
  <xref rid="ref-59" ref-type="bibr">59</xref>
 </sup>.
</p>
